Studies indicate that GBP2 significantly correlates with increased expression of multiple immune checkpoints (including PD-1 and PD-L1) and with CD8+ T cell distribution in the renal cell carcinoma tumor microenvironment, potentially promoting cancer progression (14, 111). Here, GBP2 is linked to cancer.